Combination drug-diet therapies for dyslipidemia

Translational Research

Volumn 155, Issue 5, 2010, Pages 220-227

  Rideout, Todd C ^a,b   Harding, Scott V ^a,b   Marinangeli, Christopher P F ^a   Jones, Peter J H ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; ESTROGEN; EZETIMIBE; FISH OIL; FOLIC ACID; GESTAGEN; GUAR GUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INULIN; ISPAGULA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PECTIN; PENICILLIN G; SIMVASTATIN; STANOL ESTER; STARCH; STEROL DERIVATIVE;

ADJUVANT THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET RESTRICTION; DIET THERAPY; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; FOOD INTAKE; FOOD SAFETY; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THERAPY EFFECT;

EID: 77950837754     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.12.005     Document Type: Review

References (67)

1. Teoh H., Mendelsohn A.A., Goodman S.G., et al. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Am J Cardiol 104 (2009) 798-804
2. Avisar I., Brook J.G., and Wolfovitz E. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Eur J Intern Med 19 (2008) 203-208
3. Connor W.E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 359 (2008) 530
4. Rideout T.C., Yuan Z., Bakovic M., et al. Guar gum consumption increases hepatic nuclear SREBP2 and LDL receptor expression in pigs fed an atherogenic diet. J Nutr 137 (2007) 568-572
5. Calpe-Berdiel L., Escola-Gil J.C., Ribas V., Navarro-Sastre A., Garces-Garces J., and Blanco-Vaca F. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis 181 (2005) 75-85
6. Farmer J.A. Nicotinic acid: a new look at an old drug. Curr Atheroscler Rep 11 (2009) 87-92
7. Collins N., Tighe A.P., Brunton S.A., and Kris-Etherton P.M. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr 27 (2008) 659-666
8. Wierzbicki A.S. Newer, lower, better? Lipid drugs and cardiovascular disease-the continuing story. Int J Clin Pract 61 (2007) 1064-1067
9. Reaume K.T., Erickson S.R., Dorsch M.P., et al. Effects of cerivastatin withdrawal on statin persistence. Ann Pharmacother 42 (2008) 956-961
10. Schneeweiss S., Patrick A.R., Maclure M., Dormuth C.R., and Glynn R.J. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115 (2007) 2128-2135
11. Steg P.G., Verdier J.C., Carre F., et al. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE). Arch Cardiovasc Dis 101 (2008) 723-735
12. Jenkins D.J., Kendall C.W., Faulkner D., et al. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51 (2002) 1596-1604
13. Jenkins D.J., Kendall C.W., Marchie A., et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290 (2003) 502-510
14. Denke M.A. Reviewing your investment strategy: where does diet fit in your personal portfolio. Am J Clin Nutr 81 (2005) 339-340
15. Hall W.L., Vafeiadou K., Hallund J., et al. Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 83 (2006) 592-600
16. Donnelly L.A., Palmer C.N., Whitley A.L., et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 18 (2008) 279-287
17. Jakulj L., Trip M.D., Sudhop T., von Bergmann K., Kastelein J.J., and Vissers M.N. Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels. J Lipid Res 46 (2005) 2692-2698
18. Sanchez-Muniz F.J., Maki K.C., Schaefer E.J., and Ordovas J.M. Serum lipid and antioxidant responses in hypercholesterolemic men and women receiving plant sterol esters vary by apolipoprotein E genotype. J Nutr 139 (2009) 13-19
19. Mega J.L., Morrow D.A., Brown A., Cannon C.P., and Sabatine M.S. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 29 (2009) 1310-1315
20. Hubacek J.A., Adamkova V., Prusikova M., Snejdrlova M., Hirschfeldova K., Lanska V., et al. Impact of apolipoprotein A5 variants on statin treatment efficacy. Pharmacogenomics 10 (2009) 945-950
21. Zhao H.L., Houweling A.H., Vanstone C.A., et al. Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men. Lipids 43 (2008) 1155-1164
22. Barcelos A.L., Chies R., Almeida S.E., et al. Association of CYP7A1 -278A>C polymorphism and the response of plasma triglyceride after dietary intervention in dyslipidemic patients. Braz J Med Biol Res 42 (2009) 487-493
23. Kuo P.T., Hayase K., Kostis J.B., and Moreyra A.E. Use of combined diet and colestipol in long-term (7-7 1/2 years) treatment of patients with type II hyperlipoproteinemia. Circulation 59 (1979) 199-211
24. Abumweis S.S., Barake R.I., and Jones P. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res (2008) 52
25. Kapur N.K., and Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 4 (2008) 341-353
26. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29 (2006) 1220-1226
27. de Jong A., Plat J., Lutjohann D., and Mensink R.P. Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment. Br J Nutr 100 (2008) 937-941
28. Plat J., Brufau G., Dallinga-Thie G.M., Dasselaar M., and Mensink R.P. A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients. J Nutr 139 (2009) 1143-1149
29. Gylling H., and Miettinen T.A. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects. Nutr Metab Cardiovasc Dis 12 (2002) 19-23
30. Jones P.J., Raeini-Sarjaz M., Ntanios F.Y., Vanstone C.A., Feng J.Y., and Parsons W.E. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res 41 (2000) 697-705
31. AbuMweis S.S., Vanstone C.A., Lichtenstein A.H., and Jones P.J. Plant sterol consumption frequency affects plasma lipid levels and cholesterol kinetics in humans. Eur J Clin Nutr 63 (2009) 747-755
32. Vanstone C.A., Raeini-Sarjaz M., Parsons W.E., and Jones P.J. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr 76 (2002) 1272-1278
33. Castro Cabezas M., de Vries J.H., Van Oostrom A.J., Iestra J., and van Staveren W.A. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J Am Diet Assoc 106 (2006) 1564-1569
34. Blair S.N., Capuzzi D.M., Gottlieb S.O., Nguyen T., Morgan J.M., and Cater N.B. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 86 (2000) 46-52
35. Miettinen T.A., and Gylling H. The effects of statins and sitosterols: benefit or not?. Curr Atheroscler Rep 11 (2009) 23-27
36. van Himbergen T.M., Matthan N.R., Resteghini N.A., et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 50 (2009) 730-739
37. Helske S., Miettinen T., Gylling H., et al. Accumulation of cholesterol precursors and plant sterols in human stenotic aortic valves. J Lipid Res 49 (2008) 1511-1518
38. Kidambi S., and Patel S.B. Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis. J Clin Pathol 61 (2008) 588-594
39. Shamliyan T.A., Jacobs Jr. D.R., Raatz S.K., Nordstrom D.L., and Keenan J.M. Are your patients with risk of CVD getting the viscous soluble fiber they need?. J Fam Pract 55 (2006) 761-769
40. Rideout T., Harding S.V., Jones P.J., and Fan M.Z. Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: Current understandings and future research priorities. Vasc Health Risk Manag 4 (2008) 1023-1033
41. Keenan J.M., Goulson M., Shamliyan T., Knutson N., Kolberg L., and Curry L. The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. Br J Nutr 97 (2007) 1162-1168
42. Khan A.R., Khan G.Y., Mitchel A., and Qadeer M.A. Effect of guar gum on blood lipids. Am J Clin Nutr 34 (1981) 2446-2449
43. Maki K.C., Carson M.L., Miller M.P., et al. Hydroxypropylmethylcellulose lowers cholesterol in statin-treated men and women with primary hypercholesterolemia. Eur J Clin Nutr 63 (2009) 1001-1007
44. Moreyra A.E., Wilson A.C., and Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med 165 (2005) 1161-1166
45. Rosenson R.S. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis 185 (2006) 327-330
46. Bays H.E., and Goldberg R.B. The 'forgotten' bile acid sequestrants: is now a good time to remember?. Am J Ther 14 (2007) 567-580
47. Davidson M.H. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 8 (2007) 2569-2578
48. Davidson M.H., Toth P., Weiss S., et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 24 (2001) 467-474
49. Knapp H.H., Schrott H., Ma P., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110 (2001) 352-360
50. Bays H., Rhyne J., Abby S., Lai Y.L., and Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 22 (2006) 2191-2200
51. Insull Jr. W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99 (2006) 257-273
52. Harris W.S., Miller M., Tighe A.P., Davidson M.H., and Schaefer E.J. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197 (2008) 12-24
53. Kristensen S.D., Iversen A.M., and Schmidt E.B. n-3 polyunsaturated fatty acids and coronary thrombosis. Lipids 36 (2001) S79-S82
54. Maki K.C., McKenney J.M., Reeves M.S., Lubin B.C., and Dicklin M.R. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102 (2008) 429-433
55. Barter P., and Ginsberg H.N. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 103 (2009) 435
56. Robinson J.G., and Maheshwari N. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 95 (2005) 373-378
57. Ganji S.H., Qin S., Zhang L., Kamanna V.S., and Kashyap M.L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202 (2009) 68-75
58. Kush D., Hu D.Y., Ye P., et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in asian lipid clinic patients. Cardiology 114 (2009) 192-198
59. Ballantyne C.M., Davidson M.H., McKenney J., Keller L.H., Bajorunas D.R., and Karas R.H. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 101 (2008) 1428-1436
60. Bays H.E., Neff D., Tomassini J.E., and Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 6 (2008) 447-470
61. Gazi I.F., Daskalopoulou S.S., Nair D.R., and Mikhailidis D.P. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 23 (2007) 2183-2192
62. Temel R.E., Tang W., Ma Y., et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117 (2007) 1968-1978
63. Batta A.K., Xu G., Bollineni J.S., Shefer S., and Salen G. Effect of high plant sterol-enriched diet and cholesterol absorption inhibitor, SCH 58235, on plant sterol absorption and plasma concentrations in hypercholesterolemic wild-type Kyoto rats. Metabolism 54 (2005) 38-48
64. Fahey T., Brindle P., and Ebrahim S. The polypill and cardiovascular disease. BMJ 330 (2005) 1035-1036
65. Snyder F.A. Drug combinations and all cause mortality in heart disease: dosages and types of ACE inhibitors need to be known. BMJ 331 (2005) 159
66. Horwich T. Low-density lipoprotein in the setting of congestive heart failure: is lower really better?. Curr Atheroscler Rep 11 (2009) 343-349
67. Stein E.A. After ENHANCE: is more LDL cholesterol lowering even better?. Clin Chem 54 (2008) 940-942